Key facts
- This page summarizes David Arkowitz's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 08 Feb 2022, 20:30.
David Arkowitz - 04 Feb 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Signature
- /s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz
- Issuer symbol
- MCRB
- Transactions as of
- 04 Feb 2022
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 08 Feb 2022, 20:30:39 UTC
- Previous filing
- 07 Jun 2021
- Next filing
- 31 Oct 2022
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
David Arkowitz filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 08 Feb 2022.
Change
- Previous filing in this sequence was filed on 07 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
MCRB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +190,000
- Change %
- Price
- $0.000000
- Shares after
- 190,000
- Date
- 04 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 190,000
- Exercise price
- $7.38
- Footnotes
- F1
* indicates a reported price that failed the local validity check.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter. |
Remarks:
Executive Vice President, Chief Financial Officer and Head of Business Development